• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does First Phase 3 Dosing Change The Bull Case For IDEAYA Biosciences Stock (IDYA)?

    Simply Wall St·09/19/2026 01:22:37
    Listen to the news
    • IDEAYA Biosciences and partner Servier have dosed the first patient in OptimUM-11, a global Phase 3 trial of oral PKC inhibitor darovasertib plus cMET inhibitor crizotinib as adjuvant therapy for primary uveal melanoma patients at high risk of metastasis, an area with no approved adjuvant treatments.
    • The study plans to enroll about 450 patients and uses relapse-free survival as the primary endpoint. This highlights IDEAYA Biosciences' efforts to build a broad clinical program around darovasertib across metastatic, neoadjuvant and adjuvant uveal melanoma settings while sharing development costs with Servier.
    • This article examines how IDEAYA Biosciences' investment narrative intersects with the new Phase 3 OptimUM-11 adjuvant trial in primary uveal melanoma.
    Spot 16 high quality undiscovered gems that, like IDEAYA Biosciences pushing darovasertib through late-stage trials, are quietly building high-conviction pipelines before wider attention arrives.

    What Is IDEAYA Biosciences' Investment Narrative?

    To own IDEAYA Biosciences, you need to believe this is an execution story around a focused precision oncology platform, not just a single drug bet. The Phase 3 OptimUM-11 start plugs directly into that view. It extends darovasertib into an earlier uveal melanoma setting while IDEAYA and Servier share development costs, which matters for a business that is still loss making, with net income of a US$175.02m loss on US$234.13m of revenue.

    In the short term, the bigger swing factors remain progress on the metastatic uveal melanoma NDA, how quickly partnerships translate into cash, and whether funding stays accessible given all liabilities are from higher risk sources. OptimUM-11 increases operational load and capital intensity, so trial execution and timelines now matter more to the equity story around IDYA than they did a year ago.

    Even so, there is a less comfortable angle once you look at how that funding structure could intersect with...

    There's only one way to know the right time to buy, sell or hold IDEAYA Biosciences. Head to Simply Wall St's company report for the latest analysis of IDEAYA Biosciences's Fair Value.

    NasdaqGS:IDYA 1-Year Stock Price Chart
    NasdaqGS:IDYA 1-Year Stock Price Chart

    Exploring Other Perspectives

    Three fair value estimates from the Simply Wall St Community span from US$52.38 to US$617.80 per share for IDEAYA Biosciences, which shows how far apart private investors can be. Those views were formed before the OptimUM-11 Phase 3 start and the ongoing NDA process, so you should weigh how fresh clinical and regulatory milestones could shift your own expectations and explore several contrasting viewpoints.

    Explore 2 other IDEAYA Biosciences fair value estimates, including one that suggests an upside of as much as 1508% from the current price!

    Reach Your Own Conclusion

    Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Investment Ideas Beyond IDEAYA Biosciences?

    If IDEAYA Biosciences has sharpened your focus on high conviction stories, it can help to widen the lens and compare it with other opportunities that fit different risk and income profiles. The Simply Wall St Screener can be a useful way to spot patterns across businesses rather than viewing IDYA in isolation.

    • If capital preservation comes first for you, start with a group of companies that score well on resilience and risk, such as 30 resilient stocks with low risk scores which may suit a more cautious approach.
    • If income is the priority, focus on businesses that combine higher dividend yields with stability, using a list like 6 dividend fortresses to see which payers match your comfort level.
    • If you prefer to back less crowded ideas with solid fundamentals, scan through 16 high quality undiscovered gems and compare how those quieter stories stack up against IDEAYA Biosciences on key metrics.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.